A double-blind, randomized, placebo-controlled trial of oxytocin for treatment of cognitive deficits in patients with schizophrenia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004160

Enrollment

Unknown

Registered

2014-01-13

Start date

2014-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

oxytocin group:oxytocin 20iu bid

placebo group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Schizophrenia diagnosis by DSM-4; Aged Between 18-55; The dose of antipsychotics and symptom are stable for 1 month.

Exclusion criteria

Exclusion criteria: 1. Comorbidity with other mental illness; 2. With serious and unstable somatic disease; 3. History of alcohol or drug abuse in 12 months; 4. History of ECT therapy in 3 months; 5. History of severe allergies or easy to allergies.

Design outcomes

Primary

Measure	Time frame
PANSS;CGI;MSCEIT;oxytocin;ERP;PPI;eye movemen;	—

Secondary

Measure	Time frame
SPSS;CDSS-C;RBAN;	—

Countries

China

Contacts

Public ContactWang Chuanyue

Beijing Anding hospital

wang.cy@163.net+86 13910909974

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026